Pulmosmart 400 Inhaler

Introduction

The Pulmosmart is a prescription medication that combines two active ingredients: Formoterol and Budesonide. It is available in the form of an inhaler and is primarily used for the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).

Uses

Pulmosmart is prescribed to manage and prevent symptoms associated with asthma and COPD. It helps to improve breathing by reducing inflammation in the airways and relaxing the muscles around the air passages.

Dosage and Administration

The dosage and administration of Pulmosmart should be determined by your healthcare professional based on your individual condition. Follow their instructions carefully. Generally, the recommended dose is to inhale the medication by mouth twice daily, with each inhalation separated by at least 12 hours. Make sure to shake the inhaler well before each use and rinse your mouth with water after inhalation to minimize the risk of throat irritation.

Mechanism of Action

Pulmosmart contains two active ingredients: Formoterol and Budesonide. Formoterol belongs to a class of medications called long-acting beta-agonists, which work by relaxing the muscles in the airways, making it easier to breathe. Budesonide, on the other hand, is a corticosteroid that helps to reduce inflammation in the airways, thereby reducing symptoms such as wheezing and shortness of breath.

Side Effects

Common side effects may include headache, tremor, throat irritation, cough, and hoarseness. These side effects are usually mild and temporary. However, if you experience any severe or persistent side effects, such as chest pain, rapid heartbeat, or difficulty breathing, seek medical attention immediately.

Drug Interactions

Pulmosmart may interact with certain medications, so inform your healthcare professional about all the medications you are currently taking. Some medications that may interact with Pulmosmart include beta-blockers, diuretics, and certain antidepressants. These interactions can affect the effectiveness or safety of the medications, so discuss them with your healthcare professional.

Precautions

Before using Pulmosmart, inform your healthcare professional about any medical conditions you have, especially if you have a history of heart problems, high blood pressure, diabetes, or thyroid disorders. Additionally, inform your healthcare professional about any allergies you may have, as Pulmosmart may contain inactive ingredients that could cause allergic reactions. Avoid sudden discontinuation of Pulmosmart, as it may lead to worsening of symptoms.

Storage

Patient Tips

• Follow the prescribed dosage and administration instructions provided by your healthcare professional.
• Keep track of the number of doses used to ensure you have an adequate supply.
• If you have any concerns or questions about your medication, don’t hesitate to reach out to your healthcare professional.
• Carry your inhaler with you at all times to ensure you have it readily available in case of an asthma or COPD attack.
• Do not share your inhaler with others, as it is prescribed specifically for your condition.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Budesonide tablets, capsules and granules: steroid to treat inflammation (NHS UK) [Accessed 26 Jun. 2024] (online) Available at:
• Benacort 64 micrograms Nasal Spray (Health Professionals SmPC) Available at:
• Budesonide (Drugs.com) [Accessed 6 Jun. 2024] (online) Available at:
• albuterol 90 mcg-budesonide 80 mcg/actuation hfa aerosol inhaler (RX) [Accessed 23 Jun. 2024] (online) Available at:
• Budesonide (MedlinePlus) [Accessed 28 Jun. 2024] (online) Available at:
• López-Sanromán A, Clofent J, Garcia-Planella E, Menchén L, Nos P, Rodríguez-Lago I, Domènech E. Reviewing the therapeutic role of budesonide in Crohn’s disease. Gastroenterol Hepatol. 2018 Aug-Sep;41(7):458-471. doi: 10.1016/j.gastrohep.2018.05.013. Epub 2018 Jul 12. [Accessed 3 Jun. 2024] Available at: